amlodipine has been researched along with Fatty Liver in 6 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to evaluate the effects of losartan or amlodipine alone or combined with simvastatin on hepatic steatosis degree, and on insulin sensitivity in normocholesterolemic, hypertensive patients with nonalcoholic hepatic steatosis." | 5.16 | Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2012) |
| "Non-alcoholic steatohepatitis (NASH), which is a common liver disease in industrialized countries, is associated with obesity, hypertension, and type-2 diabetes (metabolic syndrome)." | 1.35 | ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. ( Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ackerman, Z | 3 |
| Grozovski, M | 3 |
| Oron-Herman, M | 3 |
| Rosenthal, T | 3 |
| Sela, BA | 3 |
| Amir, G | 1 |
| Athyros, VG | 1 |
| Katsiki, N | 1 |
| Karagiannis, A | 1 |
| Fogari, R | 1 |
| Maffioli, P | 1 |
| Mugellini, A | 1 |
| Zoppi, A | 1 |
| Lazzari, P | 1 |
| Derosa, G | 1 |
| Pappo, O | 2 |
| Link, G | 2 |
| Toblli, JE | 1 |
| Muñoz, MC | 1 |
| Cao, G | 1 |
| Mella, J | 1 |
| Pereyra, L | 1 |
| Mastai, R | 1 |
1 trial available for amlodipine and Fatty Liver
| Article | Year |
|---|---|
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
5 other studies available for amlodipine and Fatty Liver
| Article | Year |
|---|---|
Effects of antihypertensive and triglyceride lowering agents on splenocyte apoptosis in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Bezafibrate; Blood Pressure; Captopril; Cas | 2013 |
Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.
Topics: Age Factors; Amlodipine; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Choleste | 2013 |
Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Captopril; Diet; Fatty Li | 2005 |
Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Captopril; Fatty Liver; Fructose; Hypolip | 2008 |
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2008 |